About US
Contact us
-
Roche looks for bladder cancer clues in Tecentriq's post-surgery flopWith a phase 3 trial of Tecentriq in high-risk, muscle-invasive bladder cancer patients who had already had surgery, Roche was “hoping to show we could reduce the rate of progression to metastatic di2020/5/15
-
Bristol Myers Squibb in hot water after FDA rebuffs CAR-T therapy on manufacturing concernsAs part of its $74 billion Celgene pickup, Bristol Myers Squibb offered future payouts based on FDA approval for three key pipeline assets. Already in jeopardy after one delay, that payoff looks even2020/5/14
-
Takeda touts blockbuster hopefuls, dials up cost-saving target from Shire dealAs Takeda folds in Shire, the Japanese pharma is looking into the future, which includes waves of blockbuster hopefuls, less debt and more room for cost cuts. The company is looking to launch 12 drug2020/5/14
-
BeiGene's new BTK drug Brukinsa falls short as PD-1 tislelizumab shines in busy quarterBeiGene is squaring off against industry bigwigs with its new BTK inhibitor Brukinsa, and early sales figures showjust how difficult it will be for the Chinese biotech to steal share in the U.S. mark2020/5/13
-
Are post-merger AbbVie shares 'unsustainably cheap'? One analyst thinks soWith its megamerger with Allergan finally in the books, AbbVie is officially a colossus with a bustling drug portfolio and a few strategichurdles in its immediate future. But the new AbbVie will be s2020/5/13
-
Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine workAfter winning a smallgrant for early vaccine work in March, Novavaxjustwon the largest-ever investment from CEPI, a globalcoalitionaidingCOVID-19 vaccine development. The grant of up to $384 million2020/5/12
-
Lilly cashes in on Loxo buyout with FDA approval for first-in-class cancer drug RetevmoIn two firsts, Eli Lilly has won its first approval for a pipeline drug coming out of the$8 billion acquisition of Loxo Oncology—and it's the first therapy specifically meant for cancer patients whos2020/5/12
-
Merck embarks on 3-year push to combine NJ sites into new HQMerck & Co. is preparing for a major real estate move in New Jersey. Theglobal drug giantaims to consolidate New Jersey campuses at a new headquarters in Rahway—its original HQ—by the end of 20232020/5/11
-
Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says noBack in January, Merck said Keytruda—its anti-PD-1 therapy—had missed the mark in an area where two of its rivals hadsucceeded. Both those rivals are anti-PD-L1 treatments, so could that PD-1/PD-L1 d2020/5/11
-
Pfizer, Astellas show Xtandi helps early prostate cancer patients live longerPfizer and Astellas’ Xtandi is already approved to treat nonmetastatic castration-resistant prostate cancer, thanks to data showing it can stop tumors from spreading. But now it’s adding results that2020/5/9